Gilead Sciences | GILD - Loan Capital

Stock Price
152.61
Daily Change
3.24 2.17%
Monthly
22.73%
Yearly
58.90%
Q1 Forecast
137.58

Gilead Sciences reported $22.14B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
J&J USD 39.41B 173M Sep/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 26M 6M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025